
Vertis SGR
Corso di Porta Romana, 61, Milano, Lombardia, 20121, Italy
Overview
Vertis is a dynamic and independent investment management company authorised by Bank of Italy. It manages five closed-end funds for qualified investors by participating in research projects, spin-offs, startups and PMI and deals with the investments of the innovative Made in Italy.
- Total investments
- 41
- Lead investments
- 23
- Investments · 12mo
- 8
- Active investors
- 6
Sector focus
- Digital Media
- Financial Services
- Industrial Automation
- Robotics
- Venture Capital
Investment portfolio
- Scuter
Participated · Seed · Jul 2026
Scuter developed a purpose-built cabined three-wheeled electric vehicle and launched a pilot sharing service in Milan. Over the past year it focused on platform development, vehicle homologation, industrialization and assembling an initial fleet through a predominantly Italian automotive supply chain, reaching roughly 200 vehicles. The Milan pilot produced more than 15,000 app installs, five-figure totals of trips and kilometers, about 80% of user ratings at 5/5, no observed accidents in the period, and reported reductions versus private cars of ~50% in cost, ~70% in total travel and parking time and ~90% in CO2 emissions. Scuter retains design, technology and platform management in-house while outsourcing production to the Italian supply chain. The company plans to scale via dedicated private-sharing fleets, franchised public sharing, strategic partnerships and a technology roadmap centered on AI, with further developments signposted for autumn 2026.
- Health Triage
Participated · Equity · Jul 2026
Health Triage develops artificial intelligence-based diagnostic tools for oncology and is advancing proprietary projects named Breast Negative and Prostate V-Bio. The company aims to validate its technologies clinically and integrate them into hospital workflows to make AI a routine clinical standard. Management has pursued industry-aligned financing, securing a €5M strategic investment from Fondazione ENEA Tech and Biomedical last year and a further €3M equity infusion from Vertis SGR and Health 1. Reported uses of funds include organic development of projects, ongoing clinical validation, integration into clinical workflows, market analysis, and exploration of therapeutic applications beyond diagnostics. Leadership emphasizes combining scientific rigor with industrial vision to support adoption and potential internationalization. Fin Posillipo S.p.A. is described as a supportive industrial partner in the company’s growth trajectory.
- Soource
Led · Seed · Jun 2026
Soource provides a single platform to search, enrich, automate and monitor supplier information, built on a proprietary international database of verified and certified data. Its AI system comprises multiple specialized agents handling discovery, qualification, comparison, outreach and enrichment of supplier data, and the platform is compatible with major ERPs and procurement systems like SAP Ariba and Jaggaer. The company emphasizes data quality, GDPR-compliant processing and anonymization of generic data, and states its AI falls into the EU AI Act’s zero-risk category because it only supports internal activities. Founded in 2024 in Bolzano, Soource has onboarded leading organizations across utilities, pharmaceutical, energy, insurance, food, industrial and construction sectors. Financially, the startup has raised over €5 million since 2025 and plans to use the recent Seed proceeds to accelerate product development, grow the team and expand across Europe.
- Quido
Participated · Seed · Feb 2026
Quido SRL targets the pain points of private market investors, where fragmented data sources and manual workflows slow deal sourcing and due-diligence. Its cloud-based platform acts as an AI layer that aggregates disparate information, structures it and delivers automated insights, effectively removing the “monkey work” from investment analysis. The company intends to use artificial intelligence to streamline everything from data ingestion to opportunity scoring, allowing funds and corporate investors to make faster, more informed decisions. Fresh capital will be directed toward accelerating product development, expanding the technical and commercial teams, and supporting geographic expansion beyond its initial Italian customer base. Quido has not yet disclosed revenue or user figures, but the founders emphasize product scaling as the immediate priority. The recent financing provides the first institutional backing and positions the company to move from an early prototype to a fully commercial solution. Management also plans to deepen partnerships within the Italian private-capital ecosystem through its new strategic investors.
- Butterfly Decisions
Led · Equity · Jan 2026
Butterfly Decisions is an Italian startup whose specific product offering was not detailed in the article. The company has attracted institutional interest, underscored by a recent €1.2 million financing led by Vertis sgr. While the article does not disclose operating metrics such as revenue, headcount, or user numbers, the successful raise suggests investor confidence in its growth prospects. CDP Venture Capital and a pool of business angels also joined the round, providing a diversified investor base. Although no explicit roadmap was shared, the fresh capital is expected to accelerate product development and market expansion initiatives. Further information on the company’s historical performance, customer traction, or future milestones was not provided.